A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Smith+Nephew’s IODOSORB™ Range

Shown more than twice as likely to heal wounds than standard care

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce the results of a systematic review and meta-analysis of comparative trials to determine the efficacy of its IODOSORB 0.9% Cadexomer Iodine Range* on chronic wounds versus standard care specific to the wound type.1

The review found that wounds were more than twice as likely to completely heal with IODOSORB Range than with standard care, and significantly greater reductions in wound area** were observed after 8 weeks of treatment versus standard care.

Use of IODOSORB Range helped reduce barriers to healing such as exudate, slough, pus, debris and bacteria, significantly reducing wound area** and increasing the chance of healing chronic wounds compared with standard care.1 Venous leg ulcers (VLUs), diabetic foot ulcers (DFUs) and pressure ulcers were included in the study.

“With the cost of chronic hard to heal wounds an estimated $3.9 billion in Canada, they can be a major burden on patient quality of life, healthcare resources and budgets,” said Dr. Kevin Woo, PhD, RN, Associate Professor, Queen’s School of Nursing, University of Toronto, Canada. “The data demonstrate consistent positive outcomes [IODOSORB] has on chronic stalled wounds through the removal of barriers that impede wound healing.”

The review included 13 studies comparing IODOSORB Dressings with standard care, summarising the clinical evidence supporting IODOSORB Dressings in wound bed preparation. In addition to patient comorbidities, there were a number of local factors that could act as barriers to wound healing. These included excessive exudate, cellular debris/pus/slough, and the presence of biofilm or infection.1

IODOSORB Dressing is a unique topical antimicrobial with dual-action, offering the benefits of a broad-spectrum, sustained-activity antimicrobial agent in combination with desloughing and fluid-handling properties, making it effective against biofilm in vitro and in vivo.2-28


References

  1. Woo K, Dowsett C, Costa B, Ebohon S, Woodmansey EJ, Malone M. Efficacy of topical cadexomer iodine treatment in chronic wounds: Systematic review and meta-analysis of comparative clinical trials. Int Wound J. 2021;[Epub ahead of print].
  2. Smith + Nephew 2017. Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB/IODOFLEX Dressings. Internal Report. DS/17/365/R.
  3. Skog E. et al. A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers. Br. J. Dermatol. 1983;109:77–83
  4. Moberg S, Hoffman L, Grennert ML, Holst A. A randomized trial of cadexomer iodine in decubitus ulcers. J Am Geriatr Soc. 1983;31(8):462-465.
  5. Harcup JW, Saul PA. A study of the effect of cadexomer iodine in the treatment of venous leg ulcers. Br J Clin Pract. 1986;40(9):360-364.
  6. Hillström L. Iodosorb compared to standard treatment in chronic venous leg ulcers–a multicenter study. Acta Chir Scand Suppl. 1988;544:53-56.
  7. Akiyama H, Oono T, Saito M, Iwatsuki K. Assessment of cadexomer iodine against Staphylococcus aureus biofilm in vivo and in vitro using confocal laser scanning microscopy. J Dermatol. 2004;31(7):529-534.
  8. Zhou LH, Nahm WK, Badiavas E, Yufit T, Falanga V. Slow release iodine preparation and wound healing: in vitro effects consistent with lack of in vivo toxicity in human chronic wounds. Br J Dermatol. 2002;146(3):365-374.
  9. Smith + Nephew 2017. Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB Powder. Internal Report. DS/17/363/R.
  10. Smith + Nephew 2017. Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB Ointment/Gel. DS/17/364/R.
  11. Perstorp Pharmaceuticals. Iodine release from CADEX, iodocoat and U pasta. Smith & Nephew Data on file #091101. (2009).
  12. Troëng T, Skog E, Arnesjö B, Gjöres JE, Bergljung L, Gundersen J, E. A. A randomised multicentre trial to compare the efficacy of cadexomer iodine and standard treatment in the management of chronic venous ulcers in out patients. in Cadexomer Iodine, (eds. Fox, J. & Fisher, H.) 43–50 (Schattauer Verlag, 1983).
  13. Holloway GA Jr, Johansen KH, Barnes RW, Pierce GE. Multicenter trial of cadexomer iodine to treat venous stasis ulcer. West J Med. 1989;151(1):35-38.
  14. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Cadexomer Iodine Study Group. Int J Dermatol. 1998;37(5):390-396.
  15. Ormiston MC, Seymour MT, Venn GE, Cohen RI, Fox JA. Controlled trial of Iodosorb in chronic venous ulcers. Br Med J (Clin Res Ed). 1985;291(6491):308-310. doi:10.1136/bmj.291.6491.308
  16. Smith & Nephew 2008. IODOFLEX dressings against a variety of micro-organisms grown in single and mixed species biofilms. Internal Report. 0804006.
  17. Smith & Nephew 2008. IODOFLEX dressings – disruption of a variety of micro-organisms grown in pre-established single and mixed species biofilms. Internal Report. 0804007.
  18. Oates JL, Phillips CD, Wolcott R, Woodmansey E. Effect of a Cadexomer Iodine Wound Dressing on a Chronic Wound Multi-Species Biofilm Model with Comparison to a Silver Hydrofiber Antibiofilm Dressing. in SAWC Atlanta 1 (2016).
  19. Schierle CF, De la Garza M, Mustoe TA, Galiano RD. Staphylococcal biofilms impair wound healing by delaying reepithelialization in a murine cutaneous wound model. Wound Repair Regen. 2009;17(3):354-359.
  20. Wolcott RD, Rhoads DD, Bennett ME, et al. Chronic wounds and the medical biofilm paradigm. J Wound Care. 2010;19(2):45-53.
  21. Lindsay G, Latta D, Lyons KGB. A study in general practice of the efficacy of cadexomer iodine in venous leg ulcers treated on alternate days. Acta Ther. 12, 141–148 (1986).
  22. Schwartz JA, Lantis JC 2nd, Gendics C, Fuller AM, Payne W, Ochs D. A prospective, non comparative, multicenter study to investigate the effect of cadexomer iodine on bioburden load and other wound characteristics in diabetic foot ulcers. Int Wound J. 2013;10(2):193-199.
  23. Smith + Nephew 2018. Antimicrobial activity of IODOSORB range against a broad spectrum of wound pathogens. Internal Report. 1801001
  24. Smith + Nephew 2007. An evaluation of the use of IODOSORB ointment and dressing in the management of chronic exuding wounds. Internal Report. SR/CE/027/IOD.
  25. Smith & Nephew 2018. Antimicrobial activity of IODOSORB range in a 3 day repeat challenge model. Internal Report. 1801002.
  26. Smith + Nephew 2018.Release of Iodine from IODOSORB Powder into 0.9% saline solution over a three day period. Internal Report. DS/18/024/R.
  27. Smith + Nephew 2018.Release of IODOSORB Ointment / Gel into 0.9% saline solution over a three day period. Internal Report. DS/18/025/R.
  28. Smith + Nephew 2018.Release of Iodine from IODOSORB / IODOFLEX Dressing into 0.9% saline solution over a three day period. Internal Report. DS/18/026/R.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy